LON:OXB Oxford Biomedica (OXB) Share Price, News & Analysis GBX 565 +19.00 (+3.48%) As of 12:13 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Oxford Biomedica Stock (LON:OXB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oxford Biomedica alerts:Sign Up Key Stats Today's Range 549▼ 57750-Day Range 546▼ 65452-Week Range 418▼ 952Volume359,992 shsAverage Volume871,102 shsMarket Capitalization£683.86 millionP/E RatioN/ADividend Yield4.57%Price TargetGBX 633.38Consensus RatingBuy Company Overview Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube. Read More Oxford Biomedica Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreOXB MarketRank™: Oxford Biomedica scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingBuy Consensus RatingOxford Biomedica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and no sell ratings.Upside PotentialOxford Biomedica has a consensus price target of GBX 633.38, representing about 12.1% upside from its current price of GBX 565.Amount of Analyst CoverageOxford Biomedica has only been the subject of 2 research reports in the past 90 days.Read more about Oxford Biomedica's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Oxford Biomedica is -20.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oxford Biomedica is -20.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOxford Biomedica has a P/B Ratio of 8.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for OXB. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipOxford Biomedica is a leading dividend payer. It pays a dividend yield of 4.57%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthOxford Biomedica does not have a long track record of dividend growth.Read more about Oxford Biomedica's dividend. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Oxford Biomedica to their MarketBeat watchlist in the last 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oxford Biomedica insiders have not sold or bought any company stock.Percentage Held by Insiders34.83% of the stock of Oxford Biomedica is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions32.41% of the stock of Oxford Biomedica is held by institutions.Read more about Oxford Biomedica's insider trading history. Receive OXB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OXB Stock News HeadlinesOxford Biomedica (LON:OXB) Stock Crosses Below 200-Day Moving Average - Here's WhyJuly 22, 2026 | americanbankingnews.comJust above £6 today, here’s where this deeply undervalued FTSE biotech star ‘should’ be trading right nowJune 23, 2026 | uk.finance.yahoo.comThis under $7 stock could be.Just one mile from SpaceX's launchpad sits a small company doing something SpaceX can't - and it still trades under $7. Robert Kiyosaki calls it the 'Shadow SpaceX.' His go-to financial analyst found it before institutions moved in. That window may not stay open long.July 30 at 1:00 AM | Freedom Financial (Ad)Oxford Biomedica outlines long-term growth ambitions at Capital Markets EventJune 20, 2026 | theglobeandmail.comHow Oxford Biomedica (LSE:OXB) Is Reframing Its Long Term Value Story Around £8.43May 22, 2026 | finance.yahoo.comHow I invested my first £1,000 in FTSE shares… and the mistakes I madeApril 25, 2026 | uk.finance.yahoo.com57% under ‘fair value’ and 74% forecast earnings growth! 1 FTSE high-tech med stock I just can’t pass upApril 20, 2026 | uk.finance.yahoo.comOxford Biomedica unveils fast-track viral vector service to speed gene therapy developmentApril 14, 2026 | theglobeandmail.comSee More Headlines OXB Stock Analysis - Frequently Asked Questions How have OXB shares performed this year? Oxford Biomedica's stock was trading at GBX 617 at the beginning of the year. Since then, OXB shares have decreased by 8.4% and is now trading at GBX 565. How were Oxford Biomedica's earnings last quarter? Oxford Biomedica plc (LON:OXB) released its earnings results on Thursday, March, 26th. The biopharmaceutical company reported ($26.92) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative trailing twelve-month return on equity of 48.56% and a negative net margin of 17.85%. Read the conference call transcript. How do I buy shares of Oxford Biomedica? Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Oxford Biomedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford BioMedica (OXBDF) and Barclays (BARC). Company Calendar Last Earnings3/26/2026Today7/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:OXB CIKN/A Webwww.oxfordbiomedica.co.uk Phone+44-1865-783000FaxN/AEmployees891Year FoundedN/APrice Target and Rating Average Price Target for Oxford BiomedicaGBX 633.38 High Price TargetGBX 1,140 Low Price TargetGBX 8.27 Potential Upside/Downside+12.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)GBX (26.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£143.51 million Net Margins-17.85% Pretax MarginN/A Return on Equity-48.56% Return on Assets-12.67% Debt Debt-to-Equity Ratio162.16 Current Ratio2.20 Quick Ratio1.67 Sales & Book Value Annual Sales£168.74 million Price / Sales4.05 Cash FlowGBX 187.93 per share Price / Cash Flow3.01 Book ValueGBX 67.70 per share Price / Book8.35Miscellaneous Outstanding Shares121,037,000Free FloatN/AMarket Cap£683.86 million OptionableNot Optionable Beta1.12 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (LON:OXB) was last updated on 7/30/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredBREAKING: Bill Gates Says It’s “Worth 10 Microsofts”Nvidia is up 203% this year. Microsoft, Amazon, Apple, and Alphabet have each surged between 36% and 62%. But ...Traders Agency | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe oil crisis is spreading faster than you thinkTanker traffic through Hormuz has plunged from 110-130 daily transits to near zero, while 17% of Qatar's LNG c...Golden Portfolio | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxford Biomedica With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
